Idioma:

PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy

Dermani, Fatemeh K. ; Samadi, Pouria ; Rahmani, Golebagh ; Kohlan, Alisa K. ; Najafi, Rezvan

Journal of cellular physiology, 2019-02, Vol.234 (2), p.1313-1325 [Periódico revisado por pares]

United States: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Autor: Dermani, Fatemeh K. ; Samadi, Pouria ; Rahmani, Golebagh ; Kohlan, Alisa K. ; Najafi, Rezvan
Assuntos: Animals ; Anticancer properties ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Agents, Immunological - therapeutic use ; Antitumor activity ; Apoptosis ; B7-H1 Antigen - antagonists & inhibitors ; B7-H1 Antigen - immunology ; B7-H1 Antigen - metabolism ; Cancer ; Cancer therapies ; Cell death ; Dendritic cells ; Humans ; Immune checkpoint ; immune checkpoints ; Immunity ; Immunotherapy - adverse effects ; Immunotherapy - methods ; Ligands ; Lymphocytes ; Lymphocytes B ; Lymphocytes T ; Molecular Targeted Therapy ; Natural killer cells ; Neoplasms - drug therapy ; Neoplasms - immunology ; Neoplasms - metabolism ; Neoplasms - pathology ; PD-L1 protein ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Programmed Cell Death 1 Receptor - immunology ; Programmed Cell Death 1 Receptor - metabolism ; programmed cell death protein 1 (PD‐1) ; programmed death ligand 1 (PD‐L1) ; Proteins ; Signal Transduction ; Treatment Outcome ; Tumor cells ; Tumor Escape ; Tumor Microenvironment ; Tumors
É parte de: Journal of cellular physiology, 2019-02, Vol.234 (2), p.1313-1325
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Recent studies show that cancer cells are sometimes able to evade the host immunity in the tumor microenvironment. Cancer cells can express high levels of immune inhibitory signaling proteins. One of the most critical checkpoint pathways in this system is a tumor‐induced immune suppression (immune checkpoint) mediated by the programmed cell death protein 1 (PD‐1) and its ligand, programmed death ligand 1 (PD‐L1). PD‐1 is highly expressed by activated T cells, B cells, dendritic cells, and natural killer cells, whereas PD‐L1 is expressed on several types of tumor cells. Many studies have shown that blocking the interaction between PD‐1 and PD‐L1 enhances the T‐cell response and mediates antitumor activity. In this review, we highlight a brief overview of the molecular and biochemical events that are regulated by the PD‐1 and PD‐L1 interaction in various cancers. In this review, we highlight a brief overview of the molecular and biochemical events that are regulated by the PD‐1 and PD‐L1 interaction in various cancers.
Editor: United States: Wiley Subscription Services, Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy

Dermani, Fatemeh K. ; Samadi, Pouria ; Rahmani, Golebagh ; Kohlan, Alisa K. ; Najafi, Rezvan

United States: Wiley Subscription Services, Inc

Buscando em bases de dados remotas. Favor aguardar.